I MAB (IMAB) ニュース

I-Mab to Participate at the Piper Sandler Healthcare Conference

I-Mab to Participate at the Piper Sandler Healthcare Conference PR Newswire ROCKVILLE, Md., Nov. 21, 2024 The...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

I-Mab Reports Third Quarter 2024 Results

I-Mab Reports Third Quarter 2024 Results PR Newswire ROCKVILLE, Md., Nov. 14, 2024 Givastomig data presented...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer

I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer PR Newswire ROCKVILLE, Md., Nov. 6, 2024...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

I-Mab to Release Q3 2024 Financial Results on November 14, 2024

I-Mab to Release Q3 2024 Financial Results on November 14, 2024 PR Newswire ROCKVILLE, Md., Oct. 31, 2024...

I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024

I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024 PR Newswire ROCKVILLE, Md., Oct...

I-Mab to Participate at the Truist Securities BioPharma Symposium

I-Mab to Participate at the Truist Securities BioPharma Symposium PR Newswire ROCKVILLE, Md., Oct. 28, 2024...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024

I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024 PR Newswire ROCKVILLE, Md., Sept. 16, 2024...

I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer

I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer PR...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]